VLP Therapeutics

About VLP Therapeutics

This author has not yet filled in any details.
So far VLP Therapeutics has created 48 blog entries.

VLP Therapeutics Wins Maryland Industrial Partnerships Grant Award

2017-01-11T00:18:17+00:00 2016.02.27|

Gaithersburg, Md.-- (PR NEWS WIRE) — February 27, 2016 -- VLP Therapeutics LLC (“VLP”), a Gaithersburg-based biotechnology company focusing on the research and development of therapeutic and preventative vaccines and next-generation antibody agents based upon a novel and proprietary i-α VLP vaccine technology, today announced that it received a Maryland Industrial Partnership (MIPS) grant award

VLP Therapeutics Announces Issuance of U.S. Composition of Matter Patent for i-α Virus Like Particle Platform Technology – Intellectual Property Estate Strengthens Malaria, Dengue and Zika Virus Disease Program –

2017-01-11T00:18:17+00:00 2016.02.08|

Gaithersburg, Md.—February 8, 2016 -- VLP Therapeutics, LLC. (“VLP”), a Gaithersburg-based biotechnology company, announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 9,249,191, Virus Like Particle Composition. The patent protects key composition of matter of VLP’s proprietary i-α virus like particles platform technology, and the pharmaceutical composition and vaccine for use

VLP Therapeutics to Present at 2015 Dasan Conference

2017-01-11T00:18:17+00:00 2015.12.02|

VLP Therapeutics, LLC. (“VLP”) announced that its Chief Executive Officer, Dr. Wataru Akahata, was invited to speak at the 2015 Dasan Conference in Busan, Korea on Wednesday, December 2, 2015, at 3:00 p.m. Local Time. The event, which is hosted by the Korean Federation of Science and Technology Societies (KOFST) is titled “the Development of Novel Technology for the Preparedness of Emerging and Unknown Infectious Diseases”and take place at Saintmare, Busan, Korea.

VLP Therapeutics to Present at International Conference on Vaccines R&D 2015

2017-01-11T00:18:17+00:00 2015.11.02|

VLP Therapeutics, LLC. (“VLP”) announced that its Chief Executive Officer, Dr. Wataru Akahata, will present at the International Conference on Vaccines Research and Development 2015 on Tuesday, November 3, 2015, at 4:00 p.m. Eastern Time. The event will take place at the DoubleTree by Hilton Baltimore-BWI Airport in Linthicum, Maryland.

VLP Therapeutics to Initiate Collaboration with National Cancer Center in Japan

2017-01-11T00:18:18+00:00 2015.06.04|

VLP Therapeutics, LLC. (“VLP”) announced that it has initiated a research collaboration with the National Cancer Center’s National Cancer Center Research Institute in Japan. The collaboration will help facilitate VLP’s research and development of cancer vaccine candidates.

VLP Therapeutics to Initiate Collaboration with Johns Hopkins University Bloomberg School of Public Health

2017-01-11T00:18:18+00:00 2015.06.04|

VLP Therapeutics, LLC. (“VLP”) announced that it has initiated a research collaboration with John’s Hopkins University Bloomberg School of Public Health to research VLP’s malaria vaccine candidates.

VLP Therapeutics Enters Collaboration with Institute of Tropical Medicine, Nagasaki University

2017-01-11T00:18:18+00:00 2015.04.01|

VLP Therapeutics, LLC. (“VLP”) announced that it has entered into a research collaboration with the Institute of Tropical Medicine at Nagasaki University in Japan. The collaboration will facilitate VLP’s research and development of dengue vaccine candidates.

VLP Therapeutics Enters Collaboration with Mitsubishi Heavy Industries

2017-01-11T00:18:18+00:00 2015.03.17|

VLP Therapeutics, LLC. (“VLP”), a Gaithersburg-based biotechnology company focusing on the research and development of therapeutic and preventative vaccines and next generation antibody agents based upon a novel and proprietary vaccine technology, today announced that it has entered into a collaboration with Mitsubishi Heavy Industries to facilitate VLP’s on-going research and development of virus like particles.